Am­gen's Up­liz­na suc­ceeds in Phase 3 tri­al for rare au­toim­mune dis­ease

Am­gen re­leased new Phase 3 da­ta Wednes­day for its rare dis­ease drug Up­liz­na in an au­toim­mune con­di­tion, bring­ing it po­ten­tial­ly clos­er to an­oth­er FDA ap­proval …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER